Research programme : narrow spectrum kinase inhibitors - TopiVert PharmaAlternative Names: TOP 1210
Latest Information Update: 11 May 2016
At a glance
- Originator TopiVert
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ulcerative colitis
Most Recent Events
- 09 May 2016 Preclinical trials in Ulcerative colitis in United Kingdom (unspecified route) before May 2016